Ex-GSK R&D head joins OxStem as CSO
pharmafile | September 14, 2018 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | GSK, OxStem, University of Oxford
OxStem, a regenerative drug discovery unit spun out from the University of Oxford, has brought on board ex-GlaxoSmithKline R&D exec Georg Terstappen as its new Chief Scientific Officer, which will see him assume executive responsibility for
Terstappen’s storied career has spanned 25 years and a number of big names in the industry, including Abbott, Abbvie, Bayer, GSK, and its previous incarnation GlaxoWellcome. He also co-founded drug discovery start-up Sienna Biotech and served as its CSO. At Abbvie, he served as the company’s Head of Discovery Biology, and he joins OxStem having most recently worked as GSK’s Head of Platform Technologies & Science China at the firm’s R&D Centre in Shanghai, where he held responsibility for clinical development.
Throughout his career, he has also held leadership roles in the European R&D framework, including Vice-Chair of the Innovative Medicines Strategy Group (InnoMedS) in the context of EFPIA and IMI (Innovative Medicines Initiative).
“I warmly welcome Georg to OxStem and we are thrilled to have attracted such an accomplished drug hunter to the OxStem Team,” commented Michael Stein, Chairman and CEO at OxStem. “Georg brings extensive R&D management experience to OxStem and his track record of delivery in both pharma and biotech is well-evidenced. He joins OxStem at a time of significant growth and acceleration in our discovery programmes and we look forward to working with him on our important mission to deliver innovative medicines based on the translation of our breakthrough science.”
Angela Russell, Professor of Medicinal Chemistry at the University of Oxford, and Scientific Co-founder and Director of Stemistry of OxStem, also remarked: “Georg’s experience in discovery biology and translational research, is highly complementary to the strong medicinal chemistry and deep disease area expertise of the OxStem scientific team. We look forward to a close collaboration with Georg to realise OxStem’s programme objectives.”
GSK has announced positive results from a planned interim efficacy analysis of the phase 3 …
GSK has announced that in 2024 it intends to start phase 3 trials of a …